

Resource Summary Report

Generated by T1D on Aug 2, 2026

ProMab Biotechnologies Inc.

RRID:SCR_012380

Type: Tool

Proper Citation

ProMab Biotechnologies Inc. (RRID:SCR_012380)

Resource Information

URL: <https://www.promab.com/about-us>

Proper Citation: ProMab Biotechnologies Inc. (RRID:SCR_012380)

Description: Develops and commercializes recombinant proteins and custom monoclonal antibodies through integration of bioinformatics, gene cloning, protein expression and purification, and immunology, using high-throughput technologies. ProMab applies its proteins and antibodies to deliver diagnostic products as well as services targeting the global biomedical market through collaborations with other biotechnology and bio-reagent companies.

Abbreviations: ProMab

Synonyms: ProMab Biotech, ProMab Biotechnologies

Resource Type: commercial organization, service resource

Keywords: combinant proteins, monoclonal antibodies, gene cloning, protein expression, protein purification, immunology

Resource Name: ProMab Biotechnologies Inc.

Resource ID: SCR_012380

Alternate IDs: SciEx_12644

Alternate URLs: <https://www.promab.com/>

Old URLs: <http://www.scienceexchange.com/facilities/promab-biotechnologies-inc>

Record Creation Time: 20220129T080310+0000

Record Last Update: 20260801T190439+0000

Ratings and Alerts

No rating or validation information has been found for ProMab Biotechnologies Inc..

No alerts have been found for ProMab Biotechnologies Inc..

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Antos A, et al. (2024) The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples. Scientific reports, 14(1), 3978.

Wang D, et al. (2024) A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T??cells as an off-the-shelf immunotherapy drug against B-cell malignancies. Clinical & translational immunology, 13(12), e70022.

Lowenthal MS, et al. (2024) Quantification of mRNA in Lipid Nanoparticles Using Mass Spectrometry. Analytical chemistry, 96(3), 1214.

Sawant M, et al. (2022) Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. Science translational medicine, 14(649), eabg4132.

Schilz J, et al. (2021) Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope. Journal of molecular biology, 433(18), 167113.

Landgraf KE, et al. (2020) convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting. Communications biology, 3(1), 296.

Okimoto T, et al. (2020) Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer science, 111(6), 1910.

Inao T, et al. (2019) Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer science, 110(9), 2690.

Deng Q, et al. (2019) Citrullinated Histone H3 as a Therapeutic Target for Endotoxic Shock in Mice. Frontiers in immunology, 10, 2957.

Sack BK, et al. (2017) Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice. NPJ vaccines, 2, 27.

Wan H, et al. (2015) Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nature communications, 6,

6114.

Wang S, et al. (2014) Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation. *The Journal of nutritional biochemistry*, 25(5), 515.

Hou HH, et al. (2012) N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. *Cardiovascular research*, 93(1), 120.